Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone
Expiry Date 12 months GLP1R (Glucagon-Like Peptide 1 Receptor (GLP1R)) Alternative Name GLP-1 Receptor Background Glucagon-like peptide 1 receptor, GLP-1 receptor, GLP-1-R, GLP-1R Gene ID 2740 UniProt P43220 Pathways Positive Regulation of Peptide Hormone Secretion, Hormone Transport, cAMP Metabolic Process, Feeding Behaviour Target
Acknowledgements The authors would like to thank Lotte Majbrith Badeby, Henning Gustafsson, Berit Bugge Nielsen, Lisette Gammelgaard Nielsen, Betina rtberg Olsen, Lene Von Voss and Pia Von Voss for expert technical assistance
Additionally, this treatment is not only for individuals with diabetes adults with type 2 diabetes often benefit from its blood sugar regulation properties, but it is also widely prescribed for weight loss in non-diabetic individuals
That is a treatment difference of 20 events per hour, representing approximately a 63% reduction in sleep apnea severity
Start your journey to a healthier you today by reaching out to us and discovering how Semaglutide GLP-1 can make a difference in your weight loss goals